Related Experiment Video
Updated: Feb 10, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
[Novel signal transduction pathways: the molecular basis for targeted cancer therapies in Hedgehog/Notch/Wnt pathway]
Abstract:
Aberrant activation of the Wnt, Notch and Hedgehog pathways via mutations or ligand overexpression has been implicated in a large number of cancer types where they are involved in functions ranging from tumor initiation to cancer stem cell (CSC) maintenance and angiogenesis. Agents targeting each one of these three pathways have now reached clinical trials, and the first one of these, Vismodegib, a hedgehog pathway inhibitor, was approved in 2012 by US FDA for the treatment of advanced basal cell carcinoma. Development of agents that target critical steps in these pathways as novel signal transduction pathways will be complicated by signaling cross-talk. The role that embryonic signaling pathways play in the function of CSCs, the development of new anti-CSC therapeutic agents, and the complexity of potential CSC signaling cross-talk are being explored coupled with early phase I clinical studies.
Insights
Aberrant activation of Wnt, Notch, and Hedgehog pathways drives cancer initiation and stem cell maintenance. Targeting these embryonic pathways presents therapeutic opportunities but faces challenges due to complex signaling cross-talk.
Area of Science:
- Oncology
- Developmental Biology
- Molecular Biology
Context:
- Aberrant activation of Wnt, Notch, and Hedgehog signaling pathways is implicated in numerous cancers.
- These pathways are crucial for tumor initiation, cancer stem cell (CSC) maintenance, and angiogenesis.
- Targeting agents for these pathways have advanced to clinical trials, with Vismodegib approved for advanced basal cell carcinoma.
Purpose:
- To explore the role of embryonic signaling pathways in CSC function.
- To investigate the development of novel anti-CSC therapeutic agents.
- To understand the complexity of signaling cross-talk between these pathways in cancer.
Summary:
- Mutations or overexpression of Wnt, Notch, and Hedgehog pathways contribute to cancer development and progression.
- The study examines the therapeutic potential of targeting these pathways, acknowledging the complication of signaling cross-talk.
- Early phase I clinical studies are underway to explore these therapeutic strategies and their associated complexities.
Impact:
- Advances understanding of cancer stem cell biology and therapeutic vulnerabilities.
- Highlights the potential for novel anti-cancer therapies targeting key developmental pathways.
- Addresses the critical challenge of pathway cross-talk in the development of effective cancer treatments.
Related Concept Videos
Hedgehog Signaling Pathway
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Canonical Wnt Signaling Pathway
Non-Canonical Wnt Signaling Pathways
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...

